Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A
into the hand or foot of patients with signs of critical ischemia secondary to Buerger's
disease. The injection of botulinum toxin A is carried out at the end of a single session
during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at
1, 3 and 6 months post injections.